These results highlight the therapeutic potential of targeting the c-Abl/TFEB pathway to restore lysosomal function in lysosomal storage disorders and suggest broader implications for neurodegenerative diseases associated with oxidative stress and lysosomal dysfunction. This evidence concerns the gene ABL1 and lysosomal storage disease.